6 funding opportunities found in this category. Change the order of results: Newest First Oldest First Expiring Soonest Expiring Latest Lowest Award to Highest Highest Award to Lowest
Call for Applications: Meso Foundation Research Grants
The Meso Foundation (formerly known as MARF) is the non-profit dedicated to ending the suffering caused by mesothelioma. We are the international collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to:
· Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso treatment specialists, and providing them assistance, emotional support and community with others;
· Raise awareness of meso, and advocate that the public and private sectors partner in the effort to cure it by directing the resources needed to stop this global tragedy; and
· Fund the highest quality and most promising meso research projects from around the world through rigorous peer-review. To date we have funded 86 projects, from six different countries, totaling over 8.2 million dollars.
The Meso Foundation offers research grants for two years up to $50,000 per year. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded or pending review and may be conducted through any not-for-profit academic, medical or research institution. The Foundation will review and monitor the project's progress and results, requiring semi-annual disposition of funds reports, a ten month progress report, a presentation at the Foundation’s Symposium and a full progress report at the close of the project. The Foundation seeks exceptional projects for which the Foundation's funding is demonstrated to be essential and not duplicative. Please be advised that the Foundation does not pay institutional indirect costs.
Funded researchers will also be entitled to facilitated access to the National Mesothelioma Virtual Bank (NMVB),www.mesotissue.org.They will receive expedited review of requests to use the NMVB, and they will have direct, no-cost access to materials in the bank, as well as enhanced collections from the main sites of materials.
Encouraged projects include, but are not limited to, investigations of:
1. Strategies for early detection of new or progressive disease;
2. Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment;
3. Therapeutic intervention, including but not limited to;
a. Immune Response Targeted Therapy
b. Novel chemotherapeutic compounds
c. Novel radiation or surgical techniques
4. Determination of clinical/molecular determinants for prognosis
Applications will be considered for funding by the Meso Foundation’s Science Advisory Board comprised of doctors and researchers who work around the world within the mesothelioma field. These members will review and score the research proposals based on the following criteria. The applications will be ranked numerically and the highest scoring projects will be recommended to the Foundation’s Board of Directors for funding. Based on the funding available, awards will be granted.
Applications will be evaluated on the following criteria:
Significance - Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s)- Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation - Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach - Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? If the project involves clinical research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, justified in terms of the scientific goals and research strategy proposed?
Environment - Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Applications should be submittedthrough proposalCENTRAL.You will find the Mesothelioma Applied Research Foundation listed with the instructions and the application required. Applications are limited to 10 pages (not including biographies) and are due no later than August 2, 2013. Final award decisions will be made in December 2013 and all applicants will be notified of the outcome.
Gilead Sciences Research Scholars Program in Cystic Fibrosis
Application Deadline: July 26, 2013
The mission of the Gilead Sciences Research Scholars Program in Cystic Fibrosis is to support innovative scientific research that will advance knowledge in the fields of pediatric and adult cystic fibrosis and provide support for early research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding of cystic fibrosis.
The Program provides financial support to 3 junior faculty researchers for a 2-year period. Each award is funded up to $130,000, to be paid in annual installments of up to $65,000 per year for 2 years. Funding for the second year is contingent upon submission of a progress report and approval by the Scientific Review Committee Chair.
Recipients of these competitive awards will be selected by a Committee comprised of leaders in the field of cystic fibrosis (the "Scientific Review Committee" or the "Committee"). The Committee will review complete applications and select research proposals based on their scientific merit, feasibility, mentorship, environment, and candidate. Announcement of award recipients will be made at an awards dinner hosted by the Committee and senior representatives from Gilead.
Applicants must meet the eligibility criteria in order to be considered for an award.
Eligibility
This award is intended for junior faculty who are in the early stages of their career; specifically, the Applicant may be the recipient of a career development (K) award, or another mentored research award, but not an RO1 grant or equivalent.
Applicants must meet the following requirements:
Hold an MD, DO, PhD, or equivalent degree at time of award
Be within 7 years of a faculty appointment, or an assistant professor, in association with a research institution in the United States at the time of application
Have a strong career interest in cystic fibrosis
Have a research mentor with extensive experience in the field of cystic fibrosis
Be able to devote at least 50% of professional time to research (versus administrative, patient care, or teaching responsibilities)
Be able to complete the proposed research within the 2-year award period, providing evidence (manuscript, presentation, or abstracts) for future research projects
Citizenship
An Applicant must be a citizen or permanent resident of the United States or hold a temporary nonimmigrant visa. This visa must be valid for the two-year award period (January 2, 2014 – December 31, 2015).
For general inquires about the Research Scholars Program, please call or email:
Attn: Research Scholars Program Coordinator
Telephone: 646-674-1820 Email: cfresearchscholars@contacthmc.com
If you are experiencing technical difficulties, please contact Zoomedia at 901-210-9564. If you have any other questions, please contact the Research Scholars Program Coordinator at 646-474-1820.
Advocacy Travel Awards for the International Association for the Study of Lung Cancer 15th World Conference on Lung Cancer
October 27-30, 2013 Sydney, Australia
Award Submission Deadline: June 21, 2013
In its efforts to increase links to patient advocates and advocacy organizations around the world, IASLC will offer travel awards to a limited number of patient advocates to attend and participate in the World Conference.
Applicants for the Advocacy Travel Award will be required to submit a detailed application, a summary of expected outcomes for attending, and any other supporting documentation required for review by IASLC. Organizations that have 501(c)(3) or a similar type of non-profit status, but also individuals not affiliated with an advocacy organization may apply.
Awardees will receive:
Free Conference registration
Cash Award in the amount of 1,000 AUD to help offset travel costs
Up to 4 nights accommodation at one of the Conference contracted hotels
Free IASLC Membership for 2014
Please note that if your travel costs exceed 1,000 AUD, the Conference will unfortunately not be able to provide further financial support. Any costs exceeding 1,000 AUD will be at your own expense.
Eligibility for selection in 2013 will include:
The demonstration that the organization or individual has limited financial resources -- supported through IRS form 990 submission or other documentation;
Compatibility between IASLC and the advocate or advocacy organizations’ missions, including the ability of IASLC to benefit from and contribute to the organization’s mission;
Recent and potential future partnerships or strategic endeavors;
A detailed plan and description of how information about the conference will be shared and promoted with members of the public;
Priority will be given to first-time applicants and applicants who are not already receiving funding for attendance through their own or another organization; i.e. Global Lung Cancer Coalition;
The individual applying must be a current member of IASLC for 2013 (visit www.iaslc.org/membership to join);
For organizations applying, you must nominate ONLY ONE individual to represent the organization; multiple applications from individuals from the same organization will not be considered.
Cystic Fibrosis Foundation Therapeutics, Inc. Clinical Research Awards
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the CF Foundation, offers competitive awards to support clinical research projects directly related to CF treatment and care.
Projects may address diagnostic or therapeutic methods related to CF or the pathophysiology of CF, and applicants must demonstrate access to a sufficient number of CF patients from CF Foundation-accredited care centers and to appropriate controls.
Up to $100,000 per year (plus 8% indirects) for a maximum of three years may be requested for single-center clinical research grants. For multi-center clinical research, the potential award is up to $225,000 per year (plus 8% indirects) for a maximum of three years.
For trials exceeding these limitations, please contact Cystic Fibrosis Foundation Therapeutics before submission.
Applications will be accepted only after submission and approval of a letter of intent. CFFT strictly adheres to the letter of intent and award application deadlines.
Deadlines
Fall Letter of Intent Deadline: June 1
Fall Application Deadline: Second Wednesday of September
Spring Letter of Intent Deadline: December 1
Spring Application Deadline: First Wednesday of March
Submissions
Letters of intent (LOI) should be submitted electronically at Proposal Central by 5:00 pm (EDT) on the aforementioned deadline.
Applications must be submitted electronically at Proposal Central by 5:00 pm (EDT) on the aforementioned deadline.
For More Information
Investigators interested in applying for a Clinical Research Award may contact the Grants and Contracts Office for further information and/or to discuss the potential relevance of their research to the mission of CFFT and to the objectives of these programs.
Direct inquiries to:
Cystic Fibrosis Foundation Therapeutics, Inc. Grants and Contracts Office 6931 Arlington Road Bethesda, MD 20814 (301) 951-4422 CFFTAwards@cfftherapeutics.org
Travel Awards for Young Investigators and Developing Nations Investigators for the 15th World Conference on Lung Cancer
Travel Awards will be available for Young Investigators (35 years of age or younger) and Developing Nations Investigators. These awards will consist of complimentary registration to the Conference, up to five nights accommodation at one of the Conference contracted hotels, a fixed amount to help offset travel expenses and free membership in the International Association for The Study of Lung Cancer for one year.
If you fulfill all criteria for both awards, you may apply for both; however, if selected, you will only be offered one award.
HOW TO APPLY
The candidate must be the first author and presenter of the submitted abstract
Parts of the work can be presented prior to the 15th World Conference on Lung Cancer, but the submitted abstract MUST include new information not being presented prior to WCLC 2013
Abstracts must be submitted on or before the submission deadline June 21, 2013 via the online abstract submission form on the Conference website at www.2013worldlungcancer.org
Candidates must apply at the time of abstract submission via the online submission form on or before June 21, 2013. In addition the following support materials must be sent via email to the Conference Secretariat at wclc2013@icsevents.com. Please indicate your abstract number in your application materials.
Support Materials required for Young Investigator Award Application
Proof of age (35 years of age or younger) Curriculum Vitae Statement by the senior member (who must be a member of the IASLC) of the candidate's role in the research
Support Materials required for Developing Nations Award Application
Curriculum Vitae Description of your interest and current research in lung cancer (1 - 5 pages)
DEADLINES
The deadline for submission of applications including support materials is June 21, 2013. Applications received after June 21, 2013 or applications received without support materials by June 21, 2013 cannot be considered.
CONTACT
For any inquiries, please contact wclc2013@icsevents.com.
1
